
Frontiers in Cell and Developmental Biology, Год журнала: 2025, Номер 13
Опубликована: Фев. 3, 2025
Multiple sclerosis (MS), a chronic autoimmune disorder of the central nervous system (CNS), is characterized by inflammation, demyelination, and neurodegeneration, leading to diverse clinical manifestations such as fatigue, sensory impairment, cognitive dysfunction. Current pharmacological treatments primarily target immune modulation but fail arrest disease progression or entirely reverse CNS damage. Mesenchymal stem cell (MSC) therapy offers promising alternative, leveraging its immunomodulatory, neuroprotective, regenerative capabilities. This review provides an in-depth analysis MSC mechanisms action, including regulation, promotion remyelination, neuroregeneration. It examines preclinical studies trials evaluating efficacy, safety, limitations in various MS phenotypes. Special attention given challenges delivery routes, dosing regimens, integrating MSCs with conventional therapies. By highlighting advancements ongoing challenges, this underscores potential revolutionize treatment, paving way for personalized combinatory therapeutic approaches.
Язык: Английский